One of Olivier Brandicourt’s first jobs as Sanofi’s newly appointed chief executive officer will be getting the company’s US business running smoothly as the drugmaker launches new products, chairman Serge Weinberg said in an interview with Bloomberg.
The French drugmaker on Thursday appointed Brandicourt, Bayer AG’s healthcare head, as CEO, turning to a citizen of its home country after firing Canadian-German national Chris Viehbacher in October. Brandicourt will take his new post on April 2, Paris-based Sanofi said in a statement.
Brandicourt is “a very good fit” for Sanofi and “has the experience of the portfolio businesses we have,” Weinberg said by telephone. “A lot will be about launches, not only in 2015,” and the US “is very high on the priority list,” Weinberg said.
Brandicourt, a doctor trained in Paris, has been CEO of the healthcare unit at Leverkusen, Germany-based Bayer since 2013 after rising through the ranks at Pfizer Inc to lead the US company’s emerging-markets and established-products units.
Earlier in his career, he was a malaria researcher in Paris and spent two years working as a doctor in the Republic of the Congo.
The new CEO will need to rebuild investor confidence after the abrupt ouster of Viehbacher, who was removed a month after Sanofi stock reached a record high. Brandicourt, 59, is taking the helm at a company that has predicted tepid sales growth at its key diabetes division through 2018 following a price war in the US with Novo Nordisk A/S that caused a loss of market share for its best-selling drug, Lantus.
Even as Sanofi’s key diabetes business is facing difficulty, the company said in November that by 2020 it plans to introduce 18 new products that could garner cumulative sales of 30 billion euros (US$34 billion) over the first five years. The planned introductions include Toujeo, a successor to Lantus; a cholesterol-lowering drug called Praluent; and the world’s first vaccine against dengue fever.
The US made up 34 percent of Sanofi’s US$44.9 billion in sales last year, and is where most of Sanofi’s new products will be introduced first, Weinberg said during the interview.
“The US is important to us,” he said.
Bayer CEO Marijn Dekkers praised Brandicourt for his “commitment and his contributions” to the German drugmaker.
Bayer chief strategy and portfolio officer Werner Baumann will succeed Brandicourt at the healthcare unit, the company said.
Brandicourt will be based in Paris, Weinberg said.
While Sanofi is in no need of acquisitions today and will remain “very disciplined” on dealmaking, the company could benefit by strengthening some of its businesses, Weinberg said.
“We have to be ready to seize opportunities,” he said. “I would like us to be a little bit more proactive than what we’ve been” since 2011.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day